Strongyloidiasis Outside Endemic Areas: Long-term Parasitological and Clinical Follow-up After Ivermectin Treatment

Silvia A. Repetto,1,2 Paula Ruybal,3 Estela Batalla,1 Carlota López,3 Vanessa Fridman,2 Mariela Sierra,3 Marcelo Radisic,6 Pablo M. Bravo,1,4 Marikena G. Risso,3 Stella M. González Cappa,3 and Catalina D. Alba Soto1

1Facultad de Medicina, Instituto de Investigaciones en Microbiología y Parasitología Médica, Consejo Nacional de Investigaciones Científicas y Técnicas and 2División Infectología, Hospital de Clínicas “José de San Martín,” Universidad de Buenos Aires, 3Sección Infectología, Hospital General de Agudos “Carlos G. Duran” and 4División de Enfermedades Infecciosas, Instituto de Neftrología/Nefrología, Buenos Aires, Argentina

Background. Strongyloides stercoralis affects 30–100 million people worldwide. The first-line therapy is ivermectin. Cure is defined as the absence of larvae by parasitological methods 1 year after treatment. To date, no longitudinal parasitological studies for longer periods of time have been conducted to confirm its cure. Here, we evaluated treatment response in long-term follow-up patients with chronic infection using parasitological and molecular methods for larvae or DNA detection.

Methods. A prospective, descriptive, observational study was conducted between January 2009 and September 2015 in Buenos Aires, Argentina. Twenty-one patients with S. stercoralis diagnosis were evaluated 30, 60, and 90 days as well as 1, 2, 3, and/or 4 years after treatment by conventional methods (fresh stool, Ritchie method, agar plate culture), S. stercoralis–specific polymerase chain reaction (PCR) in stool DNA, and eosinophil values.

Results. During follow-up, larvae were detected by conventional methods in 14 of 21 patients. This parasitological reactivation was observed starting 30 days posttreatment (dpt) and then at different times since 90 dpt. Eosinophil values decreased ($P = .001$) 30 days after treatment, but their levels were neither associated with nor predicted these reactivations. However, S. stercoralis DNA was detected by PCR in all patients, both in their first and subsequent stool samples, thus reflecting the poor efficacy of ivermectin at eradicating parasite from host tissues. Asymptomatic eosinophilia was the most frequent clinical form among chronically infected patients.

Conclusions. These results suggest that the parasitological cure is unlikely. Strongyloidiasis must be considered a chronic infection and ivermectin administration schedules should be reevaluated.

Keywords. strongyloidiasis follow-up; helminth molecular diagnosis; ivermectin; S. stercoralis treatment.

Strongyloides stercoralis infection is not always self-limited due to its autoinfection cycle, which leads to chronic infection. Long-term persistence of this parasitosis has been well documented among World War II former prisoners who acquired the infection in endemic areas before returning to their countries [1]. People infected with S. stercoralis who live outside endemic areas can remain asymptomatic for decades while disseminated or severe forms of the disease are found to be major complications only among the immunocompromised. In these cases, increasing numbers of circulating larvae reaching the lungs as well as adult nematodes in the intestine are commonly observed. Circulating larvae may also attain several tissues including the central nervous system. These erratic nematodes carrying their cuticle gram-negative intestinal bacteria can lead to the development of secondary bacterial infections with high mortality rates [2]. Larvae output is usually intermittent, leading to poor sensitivity of microscopic stool examination for the diagnosis and to assess the efficacy of antiparasitic therapy. Although diverse molecular methods have been developed [2], larvae visualization by microscopy remains the gold standard for diagnosis. In a recent study, we reported a specific and highly sensitive polymerase chain reaction (PCR) assay for the detection of S. stercoralis in stool samples [3].

The role of antiparasitic treatments is to control the symptomatic and to prevent the development of severe forms of the disease. Nevertheless, mebendazole requires long treatment schedules (100 mg twice daily for 4–5 days repeated at least twice) [4] while, for albendazole, cure rates of 62% and 69% have been calculated with multiple or single (400 mg) doses, respectively [4]. Presently, ivermectin is the drug of choice against S. stercoralis [5], with reported cure rates of 88% using a single oral dose (200 μg/kg/day), increasing to 96% when a second dose is administered [6, 7]. However, many reports revealed that this drug fails to attain a complete success, probably because ivermectin activity is limited to the intestinal stages.
of *S. stercoralis*, rendering its effect on the extraintestinal stages uncertain [8]. To date, no studies have been focused on evaluating the long-term response to ivermectin treatment. Moreover, ivermectin efficacy has only been assessed by conventional diagnostic methods, thus posing an additional drawback when concluding about the efficacy of this anthelminthic drug against *S. stercoralis* human infection.

Parasitological cure is currently defined as the absence of larval stages after 1 year posttreatment, but no reports have established whether *S. stercoralis* can be eradicated from the host [9, 10]. Moreover, no longitudinal parasitological studies for prolonged periods of time after parasiticide treatment have been conducted to confirm cure in patients who did not return to endemic areas.

The aim of this study was to evaluate the response to ivermectin in long-term follow-up patients with chronic strongyloidiasis without any risk of exogenous infection.

**MATERIALS AND METHODS**

**Study Design and Patients**

A prospective, descriptive, observational study was conducted between January 2009 and September 2015 in Buenos Aires, Argentina, to evaluate the clinical and parasitological evolution of strongyloidiasis after ivermectin treatment. Patients aged >18 years attending the Hospital General de Agudos Carlos G. Durand, the Instituto de Nefrología, and the Hospital de Clínicas José de San Martín, Division Infectología (Universidad de Buenos Aires [UBA]) were referred to the Clinical Parasitology Unit at the last hospital for evaluation. Stool samples were sent to the Laboratory of Clinical and Molecular Parasitology of Instituto de Investigaciones en Microbiología y Parasitología Medica (Consejo Nacional de Investigaciones Científicas y Técnicas, UBA) for parasitological diagnosis.

All subjects presented history of residence in *S. stercoralis*–endemic areas and current residence in nonendemic ones during the period studied. Northeastern and northwestern regions of Argentina and other worldwide tropical and subtropical regions were considered endemic areas [3]. All patients answered a rigorous questionnaire at each medical appointment during the follow-up, thus guaranteeing the absence of parasite reexposure risk (ie, travel to the endemic area). Those patients who returned to or visited endemic areas were withdrawn from this study.

Admission records of patients included past residence in endemic areas, clinical manifestations attributable to *S. stercoralis* infection, underlying illnesses, and complete blood and eosinophil counts. Clinical strongyloidiasis was categorized as asymptomatic, intestinal, respiratory, or severe disease (hyperinfection and disseminated forms). Eosinophilia corresponds to ≥450 cells/μL peripheral blood eosinophils. Immunological status was defined according to the presence of chronic illness, immunosuppressive or steroid therapy, hematologic malignancies, human immunodeficiency virus (HIV) infection, human T-lymphotrophic virus 1 (HTLV-1) infection, and transplantation or connective tissue diseases. HIV- and HTLV-1–infected patients were screened by enzyme immunoassays and confirmed by Western blotting. Exclusion criteria included the risk of novel exogenous infections over the last 5 years and pregnancy.

**Stool Samples**

Participants collected stool samples for 7 consecutive days in 5% formaldehyde into a single flask and separated fresh stool samples for diagnosis and follow-up. Fresh samples were stored at −20°C in our facilities [11, 12]. Details about the use of fresh, fixed, or frozen stool are provided below.

**S. stercoralis** Diagnosis: Conventional and Molecular Methods

Each technique was performed by independent operators to eliminate test interpretation bias. Patients were considered infected when rhabditoid/filariform *S. stercoralis* larvae were visualized and/or *S. stercoralis*–specific PCR was positive. A participant was considered negative when neither larvae nor PCR-specific bands were detected.

DNA isolation from fresh or frozen stool and *S. stercoralis*–specific PCR were performed on the first stool and every follow-up sample obtained from each participant.

**Microscopic Diagnosis**

One gram of fresh stool was homogenized in phosphate-buffered saline and centrifuged, and pellets were analyzed by light microscopy. Formalin-fixed stools were studied by the Ritchie method.

**Agar Plate Culture**

Fresh stool was seeded in the center of agar plates in triplicate, incubated at 37°C for up to 7 days, and examined daily under a stereomicroscope searching for larvae or their migration tracks. Worm morphology was confirmed by microscopic examination [11, 12].

**DNA Isolation**

To obtain the templates for diagnostic PCR, DNA extraction was performed on fresh or frozen stool samples using the combined method standardized in our laboratory [11]. *Trypanosoma cruzi* epimastigotes were added to each sample before DNA isolation as exogenous amplification control for the extraction and amplification processes [11].

**S. stercoralis**–Specific PCR

Amplification of a 101-bp region of *S. stercoralis* 18S small subunit ribosomal RNA gene (GenBank accession number AF279916) was performed using primers Stro 18S-1530F 5ʹ-GAATTC-CAGTAAACGTAAGTCAATTGAGC-3ʹ and Stro 18S-1630R 5ʹ-TGCCGCTTGATATTGCTCAGTTC-3ʹ [13]. PCR was performed in a final volume of 20 μL with 0.01 U/L Taq polymerase (Hot Start, Fermentas), 0.1 g/L bovine serum albumin, and
0.5 µM of each primer, and 4 µL of DNA was extracted as mentioned above as template. Cycling conditions were: 3 minutes at 95°C, 35 cycles of 45 seconds at 95°C, 1 minute at 55°C, and 45 seconds at 72°C with a final elongation of 5 minutes at 72°C. Nuclease-free water and stool DNA from healthy subjects were used as negative controls. DNA isolated from *S. stercoralis*-spiked stool was used as positive control. PCR products were visualized in agarose gels stained with GelGreen Nucleic Acid Gel Stain (Biotium) in a Molecular Imager Gel Doc XR System (BioRad).

**Exogenous Internal Amplification Control**
Trypanosoma cruzi–specific PCR was performed on clinical samples using primers TCZ1: 5ʹ-CGAGCTCTTGCCCA-CACGGGTGCT-3ʹ and TCZ2: 5ʹ-CCTCCAAGCAGCAG-3ʹ (expected product size 188 bp) as reported previously [12].

**Pharmacological Treatment**
Patients with confirmed strongyloidiasis received oral ivermectin (200 µg/kg) once a day for 2 days. Treatment was repeated after 2 weeks. Later, during the follow-up period, ivermectin was readministered only in the presence of larvae and/or symptoms. Positive PCR was not considered a criterion to start treating asymptomatic patients through the follow-up. The first 2 doses of ivermectin were administered under the physician’s supervision and the remaining doses were observed by the patient’s companion and recorded to ensure compliance.

**Follow-up**
After the first ivermectin administration, patients were reevaluated for the presence of symptoms compatible with strongyloidiasis, eosinophilia, and parasites (detected by conventional methods and PCR).

Parasitological techniques and PCR were performed 30, 60, and 90 days as well as 1, 2, 3, and 4 years after treatment.

**Statistical Analyses**
Both descriptive and inferential statistical analyses were performed using SPSS software package for Windows (version 21) and GraphPad Prism software package (version 5.03). A P value <.05 was considered statistically significant for the inferential tests. For continuous variables, data distribution was tested for normality using the Shapiro or Wilks W tests. Mean, median, and confidence interval were estimated. Nonparametric statistical tests (Wilcoxon signed-rank test, Mann-Whitney test, and Kruskal-Wallis with Dunn posttest) were used in the events where data distribution was not normal.

**Ethics Statement**
This study was approved by the Ethics Committee of the Medical School Hospital (Hospital de Clínicas José de San Martin) at UBA. Informed consents were signed by all participants before sample collection.

### RESULTS

**Study Population Profile**
Forty-eight *S. stercoralis*–infected individuals (diagnosed by conventional methods and/or PCR) were treated with ivermectin. Of them, 27 did not return for control, and 21 were followed up for a median of 730 days (IQI, 735 days) (Figure 1).

**Molecular Diagnosis Reveals the Limited Efficacy of Ivermectin for the Eradication of Strongyloidiasis**
*Strongyloides stercoralis* DNA was detected in all the stool samples obtained from all patients, both in their first sample and during the follow-up period. In contrast, larvae were detected in stool by conventional methods only in 14 of 21 follow-up patients (66.7%). Larvae were even detected during the ivermectin treatment follow-up in 4 patients whose initial diagnosis had been confirmed only by PCR since the conventional test rendered negative results.

The persistence of positive PCR in stool samples was independent of larvae observation by conventional methods and clinical manifestations. Considering ivermectin failure at eradicating *S. stercoralis* and the limited use of PCR in stool samples to detect a potentially harmful increase in parasite load, particularly among immunocompromised patients, we sought to define additional predictors of disease reactivation.

**Parasitological Follow-up of *S. stercoralis* Infection and Immunological Status**
Among the 21 patients who adhered to the follow-up, 14 (66.7%) were immunosuppressed and 7 (33.3%) immunocompetent (Table 1). Parasitological reactivation was observed at any time during the follow-up in 9 of 14 (64.3%) immunosuppressed and in 5 of 7 (71.4%) immunocompetent patients without significant

---

**Figure 1.** Evolution over time of the study population considering ivermectin treatment.

---

Downloaded from https://academic.oup.com/cid/article-abstract/66/10/1558/4817467 by William Beaumont Hospital user on 22 August 2018
Table 1. Reactivation and Clinical Manifestations During Patients Follow-up

<table>
<thead>
<tr>
<th>Patient</th>
<th>Sex/Age</th>
<th>Underlying Conditions</th>
<th>Immunosuppressive Drugs</th>
<th>Reactivation</th>
<th>Strongyloides stercoralis Larvae Detection Method (dpt)</th>
<th>Signs and Symptoms</th>
<th>Clinical Reactivation (Positive PCR Without Larvae Visualization in Stool)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>M/45</td>
<td>Tuberculosis infection</td>
<td>None</td>
<td>Parasitological and clinical</td>
<td>APC (30 and 730)</td>
<td>Asymptomatic eosinophilia</td>
<td>Asymptomatic eosinophilia (60)</td>
</tr>
<tr>
<td>2</td>
<td>F/68</td>
<td>Chronic myeloid leukemia</td>
<td>Meprednisone</td>
<td>Parasitological and clinical</td>
<td>Fresh stool (90)</td>
<td>Dyspnea and eosinophilia</td>
<td>Dyspnea and eosinophilia (60 and 730)</td>
</tr>
<tr>
<td>3</td>
<td>F/53</td>
<td>Rheumatoid arthritis</td>
<td>Meprednisone</td>
<td>Parasitological and clinical</td>
<td>Fresh stool (90 and 360)</td>
<td>Asymptomatic eosinophilia</td>
<td>Asymptomatic eosinophilia (30)</td>
</tr>
<tr>
<td>4</td>
<td>F/55</td>
<td>AIDS</td>
<td>None</td>
<td>Parasitological and clinical</td>
<td>Fresh stool (730)</td>
<td>Asymptomatic</td>
<td>Asymptomatic eosinophilia (30)</td>
</tr>
<tr>
<td>5</td>
<td>F/42</td>
<td>Leukocytoclastic vasculitis</td>
<td>Meprednisone</td>
<td>Parasitological and clinical</td>
<td>APC (360)</td>
<td>Asymptomatic eosinophilia</td>
<td>Asymptomatic eosinophilia (30)</td>
</tr>
<tr>
<td>6</td>
<td>F/65</td>
<td>Primary biliary cirrhosis</td>
<td>Meprednisone</td>
<td>Parasitological and clinical</td>
<td>Fresh stool and APC (360)</td>
<td>Pneumonia and septic shock(a)</td>
<td>...</td>
</tr>
<tr>
<td>7</td>
<td>M/62</td>
<td>Rheumatoid arthritis</td>
<td>Etanercept</td>
<td>Parasitological</td>
<td>APC (360)</td>
<td>Asymptomatic eosinophilia</td>
<td>...</td>
</tr>
<tr>
<td>8</td>
<td>F/37</td>
<td>None</td>
<td>None</td>
<td>Parasitological</td>
<td>Fresh stool and APC (90 and 730)</td>
<td>Asymptomatic eosinophilia</td>
<td>...</td>
</tr>
<tr>
<td>9</td>
<td>M/32</td>
<td>None</td>
<td>None</td>
<td>Parasitological</td>
<td>APC (360)</td>
<td>Asymptomatic eosinophilia</td>
<td>...</td>
</tr>
<tr>
<td>10</td>
<td>F/54</td>
<td>None</td>
<td>None</td>
<td>Parasitological</td>
<td>APC (500)</td>
<td>Asymptomatic eosinophilia</td>
<td>...</td>
</tr>
<tr>
<td>11</td>
<td>M/47</td>
<td>None</td>
<td>None</td>
<td>Parasitological</td>
<td>APC (30 and 730)</td>
<td>Asymptomatic eosinophilia</td>
<td>...</td>
</tr>
<tr>
<td>12(a)</td>
<td>M/31</td>
<td>AIDS</td>
<td>None</td>
<td>Parasitological</td>
<td>APC (360 and 1095)</td>
<td>Asymptomatic</td>
<td>...</td>
</tr>
<tr>
<td>13</td>
<td>F/67</td>
<td>None</td>
<td>None</td>
<td>Parasitological</td>
<td>APC (30)</td>
<td>Asymptomatic</td>
<td>...</td>
</tr>
<tr>
<td>14(a)</td>
<td>M/45</td>
<td>AIDS</td>
<td>None</td>
<td>Parasitological</td>
<td>APC (360)</td>
<td>Asymptomatic</td>
<td>...</td>
</tr>
<tr>
<td>15(a)</td>
<td>F/63</td>
<td>Kidney transplant recipient</td>
<td>Meprednisone</td>
<td>Clinical</td>
<td>...</td>
<td>...</td>
<td>Escherichia coli sepsis and eosinophilia (90)</td>
</tr>
<tr>
<td>16(a)</td>
<td>F/59</td>
<td>Giant-cell arteritis</td>
<td>Meprednisone</td>
<td>Clinical</td>
<td>...</td>
<td>...</td>
<td>Peritonitis (360)(b)</td>
</tr>
<tr>
<td>17(a)</td>
<td>M/30</td>
<td>AIDS</td>
<td>None</td>
<td>Clinical</td>
<td>...</td>
<td>...</td>
<td>Asymptomatic eosinophilia (30)</td>
</tr>
<tr>
<td>18(a)</td>
<td>M/46</td>
<td>AIDS</td>
<td>None</td>
<td>No reactivation</td>
<td>...</td>
<td>...</td>
<td>...</td>
</tr>
<tr>
<td>19</td>
<td>M/45</td>
<td>None</td>
<td>None</td>
<td>No reactivation</td>
<td>...</td>
<td>...</td>
<td>...</td>
</tr>
<tr>
<td>20(a)</td>
<td>M/64</td>
<td>AIDS</td>
<td>None</td>
<td>No reactivation</td>
<td>...</td>
<td>...</td>
<td>...</td>
</tr>
<tr>
<td>21</td>
<td>M/65</td>
<td>None</td>
<td>None</td>
<td>No reactivation</td>
<td>...</td>
<td>...</td>
<td>...</td>
</tr>
</tbody>
</table>

Abbreviations: APC, agar plate culture; dpt, days posttreatment; F, female; M, male; PCR, polymerase chain reaction.

\(a\)Immunosuppressed patient.

\(b\)Deceased patient.
associations between parasitological reactivation and immunological status (Fisher test $P = .57$; Figure 2A). Among the immunosuppressed patients with disease reactivation, 3 were positive for HIV and none for HTLV-1 (data not shown).

Regarding the parasitological method for *S. stercoralis* detection among the immunosuppressed patients, larvae were detected by agar plate culture (APC) in 5 of 9 (55.6%) patients, in fresh stool samples in 3 of 9 (33.3%) patients, and in 1 patient by both methods. Among the immunocompetent patients, larvae were detected by APC in 4 of 5 (80%) patients and by fresh stool examination in 1 patient who was also positive by APC (20%) (Figure 2B).

**Parasite Burden and Clinical Manifestations**

The first round of ivermectin treatment was consistently followed by a temporary decrease in parasite burden. Indeed, larvae were not detected in stool by parasitological methods 15 days posttreatment (dpt) (Figure 2C). Thereafter, parasitological reactivation was detected by fresh stool microscopic examination or APC starting at 30 dpt and then at different times since 90 dpt (Figure 2C and D; Table 1). Such variations in parasite load were independent of patients' immune status. Furthermore, even though patients received additional rounds of ivermectin after parasitological reactivation, 8 patients had $>$1 episode of reactivation after etiological treatment.

Table 1 shows the diverse clinical manifestations observed in patients with chronic infection. Those with parasitological reactivation may present without any symptoms or only with eosinophilia. However, severe forms of infection may occur in immunocompromised patients. Clinical reactivation of the disease was defined as the recurrence of symptoms and/or eosinophilia without larvae visualization in fresh stool or by APC. In addition, 4 patients showed neither parasitological nor clinical reactivation even when all their stool samples collected during the follow-up were PCR positive.

**Use of Eosinophilia as a Parasitological Reactivation Marker**

Parasite persistence after ivermectin treatment as detected by PCR reveals the chronic trait of this infection which, in addition, involves fluctuating parasitic burden. In this context, we evaluated the potential use of eosinophil count for predicting a harmful rise in larvae burden. Eosinophil counts decreased significantly in all patients 30 dpt even though normal values were not reached in all the patients (pretreatment median, 1774 eosinophils/μL [interquartile range, 1097]; posttreatment median, 554.5 eosinophils/μL [interquartile range, 381.8]; $P = .001$; Figure 3A). No significant differences were observed in eosinophil values between immunocompromised and non-immunocompromised patients during the follow-up (Wilcoxon test $P = .47$; Figure 3B and 3C). The dispersion of eosinophil counts among the immunocompromised individuals is noteworthy, as these values may vary according to their underlying condition.

**Figure 2.** A, Parasitological reactivation according to immune status considering the follow-up. B, Conventional diagnosis of *Strongyloides stercoralis* in stool samples. C and D, Time scale of different parasitological reactivation episodes in immunosuppressed (IMM-S) and immunocompetent (IMM-C) patients (C and D, respectively). Gray squares: larvae observation in fresh stool/agar plate culture (APC) and positive polymerase chain reaction (PCR). White squares: No larvae observation by conventional method; only positive PCR. Day 0: initial time of *S. stercoralis* diagnosis and ivermectin treatment.
Several studies focused on evaluating ivermectin efficacy for strongyloidiasis have already been published [14–24]. However, none of them performed molecular methods or long-term parasitological clinical follow-up to confirm parasitological cure in patients who did not return to endemic areas.

Treatment options for uncomplicated strongyloidiasis are thiabendazole, albendazole, and ivermectin, with the latter being the drug of choice for this parasitosis [14, 15]. Two oral doses of 200 mg/kg/day is the scheme most frequently used to treat asymptomatic/intestinal forms [14]. Table 2 shows some representative studies based on parasitological methods of limited sensitivity to assess ivermectin efficacy in which post-treatment response does not always reach 100% [16–24]. In our laboratory, a molecular method such as PCR with steady positive results in stool reveals that the current treatment diminishes parasite load but does not eliminate the parasite from the host, thus confirming *S. stercoralis* persistence at low parasite burden and progression to chronic infection. Furthermore, in 67% of our study population, larvae were visualized by conventional parasitological methods at least once during the posttreatment follow-up. Parasitological reactivations were documented mostly 1 year posttreatment or later, indicating that shorter observation periods may be insufficient to detect the whole dimension of treatment failure.

On the other hand, APC and Baermann methods have been recommended by different authors for the posttreatment follow-up [9, 10, 15]. Our results show that the frequency of parasitological reactivation is similar among immunocompetent and immunocompromised patients. Thereafter, every patient should be followed up regularly by APC and, in the event of an increase in parasite burden detected by using this technique, antiparasitic treatment should be indicated.

Persistence of parasite DNA detection by PCR among our patients with such high rates of recurrence of larvae detection in stool samples strongly indicates the ineffectiveness of ivermectin at eliminating the parasite from the host. Therefore, a high sensitivity technique such as the conventional PCR can be suitable for early diagnosis but not for the posttreatment monitoring of *S. stercoralis* infection. It would be optimal to have a sensitive and specific method to quantify parasite load in stool to predict parasite reactivation accurately.

Nuesch et al [25] reported that monitoring of blood eosinophil count may also be an effective tool to predict therapeutic success as a significant decrease is achieved after treatment. When eosinophilia was evaluated here as an immunological marker to predict parasite reactivation, 3 criteria were chosen for the analysis: initial counts, 30 dpt, and long term follow-up. As we have described previously, the presence of eosinophilia at the time of diagnosis increased the probability of infection
by *S. stercoralis* by 6.24-fold, and values decreased significantly after 30 dpt [4]. This response to ivermectin is an indirect confirmation of parasite infection and parasite load reduction. In this small cohort, eosinophilia is not a marker for long-term follow-up as changes in this parameter are not significant except for some particular cases. Moreover, eosinophil levels may remain low in patients with either parasitological or clinical reactivation, regardless of their immunological status.

Due to the lack of a suitable marker and the sporadic larval excretion, parasitological studies should be performed as frequently as possible in all of the patients with clinical symptoms compatible with strongyloidiasis. In this context, patients should be monitored posttreatment at least every 3 months during the first year and then twice a year. This control should be more frequent in immunocompromised patients to avoid severe forms of infection.

The difficulty in *S. stercoralis* elimination from the host relies on several causes. First, its autoinfective cycle favors parasite establishment. Second, the immune response is directed against the filariform infective L3 larvae, which possesses a different antigen pattern from L3a, the autoinfective larvae. Therefore, L3a is able to evade the immune response, thus favoring the establishment of chronic infection [26]. Third, larval diapause with periodic reactivations in tissues has been suggested by several authors [27, 28]. Finally, experimental models of *S. stercoralis* infection suggest that ivermectin is effective against adult worms but less effective against eggs and larval stages at tissue levels [8, 9, 29]. In view of the duration of the autoinfective cycle (2–4 weeks), the administration of 2 doses of ivermectin 2 weeks apart was adopted as a current practice as shown in Table 2. Our results suggest that administration of additional rounds of ivermectin could be implemented to kill female worms to eradicate L3a stages. Further studies are required to evaluate the effectiveness of this ivermectin schedule, and quantitative methods of high sensitivity and accuracy are needed to monitor treatment success or to predict reactivation. These results reveal the tip of the iceberg for future and in-depth studies focused on achieving the cure of this neglected disease.

### Notes

**Financial support.** This work was supported by grants from Agencia Nacional de Promoción Científica y Tecnológica (PICT 2013-0698) and Universidad de Buenos Aires (UBACYT 20020130100753BA-2014).

**Potential conflicts of interest.** All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

### References


### Table 2. Studies on Ivermectin Efficacy to *Strongyloides stercoralis* Treatment

<table>
<thead>
<tr>
<th>Ivermectin Description</th>
<th>Patients, No.</th>
<th>Follow-up Duration</th>
<th>Parasitological Method</th>
<th>Posttreatment Response, No. (%)</th>
<th>Reinfec tion Risk</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Single dose, 100 μg/kg/day</td>
<td>22</td>
<td>3 months</td>
<td>APC</td>
<td>17 (25)</td>
<td>None</td>
<td>[16]</td>
</tr>
<tr>
<td>Two doses, 200 μg/kg/day</td>
<td>35</td>
<td></td>
<td></td>
<td>35 (100)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Single dose, 150–200 μg/kg/day</td>
<td>29</td>
<td>30 days</td>
<td>Fresh stool and Kato smears, formalin and Baermann technique</td>
<td>24 (83)</td>
<td>None</td>
<td>[17]</td>
</tr>
<tr>
<td>Single dose, 200 μg/kg/day</td>
<td>16</td>
<td>Up to 30 months</td>
<td>Fresh stool and Baermann technique</td>
<td>16 (100)</td>
<td>None</td>
<td>[18]</td>
</tr>
<tr>
<td>Two doses, 200 μg/kg/day</td>
<td>18</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Single dose, 200 μg/kg/day</td>
<td>152</td>
<td>3 weeks</td>
<td>Baermann technique</td>
<td>126 (82.8)</td>
<td>Yes</td>
<td>[19]</td>
</tr>
<tr>
<td>Two doses, and repeat 2 weeks apart, 6 mg/day</td>
<td>67</td>
<td>12 months</td>
<td>Formalin-ether concentration, Harada-Mori fecal culture</td>
<td>65 (97)</td>
<td>Yes</td>
<td>[20]</td>
</tr>
<tr>
<td>Single dose, 150–200 μg/kg/day</td>
<td>78</td>
<td>30 days</td>
<td>APC</td>
<td>77 (98.7)</td>
<td>Yes</td>
<td>[21]</td>
</tr>
<tr>
<td>Single dose, 200 μg/kg/day</td>
<td>106</td>
<td>6 months</td>
<td>APC and IFAT</td>
<td>75 (70.8)*</td>
<td>30 (87.5)*</td>
<td>None</td>
</tr>
<tr>
<td>Single dose, 200 μg/kg/day</td>
<td>31</td>
<td>39 (2–74 weeks)</td>
<td>Direct microscopic, formalin-ether concentration, modified Koga APC</td>
<td>30 (96.8)</td>
<td>ND</td>
<td>[23]</td>
</tr>
<tr>
<td>Two doses, and repeat 2 weeks apart, 200 μg/kg/day</td>
<td>29</td>
<td>26 (2–74 weeks)</td>
<td></td>
<td>27 (93.1)</td>
<td>None</td>
<td></td>
</tr>
<tr>
<td>Single dose, 6 mg</td>
<td>21</td>
<td>4 weeks</td>
<td>APC</td>
<td>19 (90.5)</td>
<td>ND</td>
<td>[24]</td>
</tr>
</tbody>
</table>

Abbreviations: APC, agar plate culture; IFAT, immune fluorescence antibody test; ND, not determined.

* Cure criteria: decreased serologic titer only.
* Cure criteria: negative stool culture.